← Back to All Filings

Myriad Genetics CAO Files Exit Form, Ceases Insider Reporting

Low SignificanceOctober 24, 2025 at 4:34:32 PM EDT

MYRIAD GENETICS INC

$MYGN4CIK: 0000899923

Subscribe to track MYGN

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Myriad Genetics CAO Files Exit Form

Company: MYRIAD GENETICS INC (MYGN) Form: 4 | Filed: 2025-10-24 Significance: Low

Insider: Munk Natalie Title: Chief Accounting Officer | Relationship: Officer

Transaction: • Type: Exit Filing (No Transaction) • Shares: 0 • Price: N/A • Value: $0 • Owned After: 45,167

Key Insight: This is an 'Exit' filing indicating that Chief Accounting Officer Natalie Munk is no longer a Section 16 reporting person, likely due to her departure from the role. No shares were traded.

Market Context: The departure of a key financial officer can be a point of interest for investors. The officer retains a holding of 45,167 shares.

Comprehensive Analysis

SEC Filing Analysis: MYRIAD GENETICS INC (MYGN)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Chief Accounting Officer Natalie Munk has filed an "Exit" Form 4, indicating she is no longer a Section 16 officer as of October 24, 2025. This filing does not report any new transactions.
  • Market Impact: Neutral, as no shares were bought or sold. The underlying event—the departure of a key executive—may be monitored by investors for signs of management instability.

Company Information

FieldValue
CompanyMYRIAD GENETICS INC
Ticker SymbolMYGN
CIK0000899923
IndustryIn Vitro & In Vivo Diagnostic Substances

Insider Information

FieldValue
NameMunk Natalie
CIK0001932320
Title/PositionChief Accounting Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-10-24
Transaction CodeN/A (Exit Filing)
Security TypeCommon Stock
Shares Involved0
Price Per ShareN/A
Total Value$0
Shares Owned After45,167
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.0%
Shares Transacted0
% of Shares Outstanding0.0%
Post-Transaction Ownership45,167 shares (0.049% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a small-cap company like Myriad Genetics ($0.75 billion market cap), the departure of a C-suite officer can be more notable than at a larger corporation. However, this filing itself has no direct financial impact.
  • Ownership Concentration: The departing officer's ownership is negligible at 0.049% of shares outstanding, indicating her holdings do not represent a significant control stake.
  • Transaction Significance: The filing is informational and carries low trading significance. It merely formalizes the end of the insider's reporting requirements.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The filing reports no transaction, so there is no direct price pressure from a sale or purchase. The market's reaction will be tied to the news of the officer's departure itself, not this filing.

Volume & Sentiment

  • Expected Volume Impact: Minimal. This type of filing typically does not drive trading volume.
  • Sentiment Indicator: Neutral. The filing is a procedural notification rather than a bullish or bearish signal.

Investment Insights

Positive Market Indicators

  • None directly from this filing.

Risk Factors

  • The departure of a Chief Accounting Officer could signal potential management or operational instability, which warrants monitoring.

Key Takeaways

  1. No Trade Occurred: This is an administrative filing confirming Natalie Munk is no longer a Section 16 insider.
  2. Executive Departure: The filing confirms the departure of the Chief Accounting Officer from her role.
  3. Minor Holding: The insider retains a small position of 45,167 shares, which is not a significant portion of the company's outstanding stock.

Additional Context

Transaction Notes

  • Special Circumstances: The filing's remarks explicitly state: "This 'Exit' Form 4 is voluntarily filed to report solely that, effective on October 24, 2025, the Reporting Person no longer serves in the role of Chief Accounting Officer of the Company, and therefore is no longer subject to Section 16 reporting."
Topics:#SECFiling#Form4#MYGN#MyriadGenetics#InsiderTrading#ExecutiveMove#CorporateGovernance#StockMarket#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.